Screener
CRISPR Therapeutics CRSP Retained Earnings
Retained Earnings at other companies
Other financials
Where this comes from
Reported directly by CRISPR Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.
The source filing: CRISPR Therapeutics’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 4:48 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-204188
| Line item | As of / March 31, 2026 | As of / December 31, 2025 |
|---|---|---|
| Shareholders’ equity: | ||
| Common shares, CHF 0.03 nominal value, 132,477,166 shares authorized at March 31, 2026 and at December 31, 2025, 96,500,822 and 96,009,657 shares issued at March 31, 2026 and December 31, 2025, respectively, 96,385,506 and 95,894,341 shares outstanding at March 31, 2026 and December 31, 2025, respectively | 3,115 | 3,087 |
| Treasury shares, at cost, 115,316 shares at March 31, 2026 and at December 31, 2025 | (60) | (60) |
| Additional paid-in capital | 3,883,924 | 3,861,516 |
| Accumulated deficit | (2,070,482) | (1,947,551) |
| Accumulated other comprehensive (loss) income | (1,941) | 4,821 |
| Total shareholders’ equity | 1,814,556 | 1,921,813 |
| Total liabilities and shareholders’ equity | $2,725,820 | $2,265,243 |
Item 1. Financial Statements
FAQ
- What is CRISPR Therapeutics's retained earnings?
- CRISPR Therapeutics (CRSP) reported retained earnings of -$2.07B in Q1 2026.
- How has CRISPR Therapeutics's retained earnings changed year-over-year?
- CRISPR Therapeutics's retained earnings decreased by 37.9% year-over-year, from -$1.5B to -$2.07B.
- What is the long-term trend for CRISPR Therapeutics's retained earnings?
- Over 5 years (2020 to 2025), CRISPR Therapeutics's retained earnings has grown at a 27.7% compound annual growth rate (CAGR), from -$573.58M to -$1.95B.
- What does retained earnings mean?
- Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.
Ask your AI about CRISPR Therapeutics's retained earnings.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude